Form 4: Nuvalent CFO Executes Pre-Planned Stock Option Exercise and Share Sales

Nuvalent, Inc.'s Chief Financial Officer, Alexandra Balcom, executed pre-planned transactions, exercising stock options and selling Class A Common Stock on July 15 and 16, 2025, under a Rule 10b5-1 trading plan.

Summary

• Nuvalent, Inc. Chief Financial Officer Alexandra Balcom acquired a total of 20,000 shares of Class A Common Stock through the exercise of stock options at an exercise price of $18.93 per share on July 15 and July 16, 2025.
• Concurrently, Ms. Balcom sold a total of 20,000 shares of Class A Common Stock on the open market on July 15 and July 16, 2025.
• On July 15, 2025, 5,300 shares were acquired and 5,300 shares were sold at weighted average prices ranging from $82.67 to $85.48.
• On July 16, 2025, 14,700 shares were acquired and 14,700 shares were sold at a weighted average price of $85.10.
• All transactions were conducted pursuant to a Rule 10b5-1 trading plan adopted on December 12, 2024.
• Following these transactions, Ms. Balcom beneficially owns 61,734 shares of Class A Common Stock directly.
• Ms. Balcom also holds 67,000 unexercised stock options with an exercise price of $18.93, which vest over time with 25% vested on January 4, 2023, and the remainder vesting monthly over three years thereafter.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it involves insider selling, it is part of a pre-planned 10b5-1 strategy, which is a common and expected practice for managing equity compensation. The significant difference between the option exercise price and the sale price is positive for the executive, reflecting value creation from their equity holdings.

Positives

• The transactions demonstrate the exercise of vested stock options, indicating the realization of value from long-term incentive compensation.
• The sales were executed at significantly higher prices ($82.67 $85.48) than the option exercise price ($18.93), indicating a substantial gain for the reporting person.
• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, which helps mitigate concerns about insider trading based on non-public information.

Negatives

• The sale of shares by a Chief Financial Officer could be interpreted by some investors as a reduction in direct equity exposure, although it is part of a pre-planned strategy.

Risks

• The weighted average prices for share sales indicate that the actual sale prices varied, exposing the seller to market price fluctuations within the specified ranges.
• Future market conditions could impact the value of the remaining beneficially owned shares and unexercised options.

Future Outlook

NA

Industry Context

This Form 4 filing reflects routine insider transactions for equity compensation and does not provide specific industry context or trends. Such transactions are common across all industries for executives managing their equity holdings.

Stakeholder Impact

• Shareholders may view the sale of shares by a CFO as a routine part of equity compensation management, especially given the Rule 10b5-1 plan, which generally mitigates concerns about opportunistic selling.

Key Dates

Recommendation

Keywords

Nuvalent Inc., NUVL, SEC Form 4, Insider Trading, Stock Option Exercise, Share Sale, Rule 10b5-1 Plan, Chief Financial Officer, Alexandra Balcom, Equity Compensation